Pharmaceutical Companies(BK7508),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

BK7508 Pharmaceutical Companies

Trading 11-15 10:10:16 AEDT

922.00

-20.24

-2.15%

High940.36	Low921.54	Vol9.09M
Open940.30	D1 Closing942.24	Amplitude2.00%
Mkt Cap0.00	Tradable Cap0.00	Total Shares0.00
T/O51.16M	T/O Rate--	Tradable Shares0.00
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":922.0015,"timestamp":1731625816084,"preClose":942.2422,"halted":0,"volume":9094917,"delay":0,"changeRate":-0.021481,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-20.240662,"latestTime":"11-15 10:10:16 AEDT","open":940.3034,"high":940.36115,"low":921.54,"amount":51156622,"amplitude":0.019975,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1731646800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1731625200000,1731646800000]],"turnoverRate":0.000224,"increases":11,"decrements":7,"flats":25,"marketCap":146564467096,"floatMarketCap":143748506445.5},"requestUrl":"/m/hq/s/BK7508/wiki","defaultTab":"wiki","newsList":[{"id":"2483333159","title":"New Forecasts: Here's What Analysts Think The Future Holds For Neuren Pharmaceuticals Limited (ASX:NEU)","url":"https://stock-news.laohu8.com/highlight/detail?id=2483333159","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483333159?lang=en_us&edition=fundamental","pubTime":"2024-11-15 04:00","pubTimestamp":1731614419,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals Limited  shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts. The consensus estimated revenue numbers rose, with their view now clearly much more bullish on the company's business prospects. Neuren Pharmaceuticals has also found favour with investors, with the stock up a noteworthy 20% to AU$17.30 over the past week. Could this upgrade be enough to drive the stock even higher?Following the latest upgrade, the current consensus, from the six analysts covering Neuren Pharmaceuticals, is for revenues of AU$163m in 2024, which would reflect a considerable 16% reduction in Neuren Pharmaceuticals' sales over the past 12 months. Before the latest update, the analysts were foreseeing AU$123m of revenue in 2024. The consensus has definitely become more optimistic, showing a very substantial lift in revenue forecasts.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/forecasts-heres-analysts-think-future-200019637.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK4109","NEU.AU","NEU","BK7508","BK7096"],"gpt_icon":0},{"id":"2483806921","title":"Immutep ADRs Climb on Positive Efti Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2483806921","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483806921?lang=en_us&edition=fundamental","pubTime":"2024-11-14 22:10","pubTimestamp":1731593400,"startTime":"0","endTime":"0","summary":"Immutep's American depositary receipts jumped after the company reported positive data from a trial evaluating its drug Efti in combination with Merck's therapy Keytruda for treating non-small cell lung cancer.The stock was up 12% at $2.10 in premarket trading. Shares had fallen 22% year-to-date when the market closed Wednesday.The biotechnology company said before the bell that mature survival data for patients treated with the combination were well above historical controls and exceeded expectations.\"We are encouraged to see Efti build upon the historical clinical outcomes from the most widely used immunotherapy-chemo combination today,\" Chief Executive Marc Voigt said.Early evaluations of an expanded cohort of trial patients are also tracking well, Voigt said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","LU1934455194.USD","IE00BLSP4239.USD","LU0861579265.USD","LU1066051498.USD","MRK","LU0965509010.AUD","LU1941712264.USD","IE00BSNM7G36.USD","BK7508","IE00B2B36J28.USD","LU1066051225.USD","SG9999015358.SGD","SG9999001440.SGD","LU1430594728.SGD","LU0265550946.USD","BK7067","LU1917777945.USD","LU0006306889.USD","LU0211331839.USD","IE00BBT3K403.USD","LU0070302665.USD","LU1585245621.USD","BK4533","SG9999013999.USD","IE0002141913.USD","SG9999014542.SGD","LU1934455863.HKD","LU0234572021.USD","LU2106854487.HKD","IE000M9KFDE8.USD","LU2361044865.SGD","IE00BN8TJ469.HKD","LU1093756168.USD","LU0106261372.USD","LU1989771016.USD","LU1057294990.SGD","LU2112291526.USD","BK4007","LU0266013472.USD","LU2361045086.USD","LU1066051811.HKD","LU0265550359.USD","BK4588","LU0985320562.USD","LU2089984988.USD","SG9999002224.SGD","SG9999014567.USD","IMMP","LU1989772923.USD"],"gpt_icon":0},{"id":"2483447870","title":"BRIEF-Positive Data From Phase II Trial In Soft Tissue Sarcoma Presented At CTOS 2024 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2483447870","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483447870?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:19","pubTimestamp":1731590345,"startTime":"0","endTime":"0","summary":"Nov 14 (Reuters) - Immutep Ltd   :   * POSITIVE DATA FROM PHASE II TRIAL IN SOFT TISSUE SARCOMA PRESENTED AT CTOS 2024 ANNUAL MEETINGSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","IMM.AU","BK7067"],"gpt_icon":0},{"id":"2483760870","title":"Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2483760870","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483760870?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:15","pubTimestamp":1731590100,"startTime":"0","endTime":"0","summary":"Mature data in patients with a minimum follow-up of 22 months  shows excellent results, well above historical controls and exceeding expectations:. Median Overall Survival is 32.9 months, with median Progression Free Survival reaching 12.7 months, and a 24-month Overall Survival rate of 81.0%. Data from all evaluable patients to date  demonstrates significant improvement of Overall Response Rate compared to historical controls. Safety continues to be favourable with no new safety signals. INSIGHT-003, which is nearing completion of enrolment, evaluates efti with the most widely used immunotherapy-chemo combination today in a similar population to upcoming TACTI-004 Phase III trial. SYDNEY, AUSTRALIA, Nov. 14, 2024  -- Immutep Limited  , a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces positive data from the investigator-initiated INSIGHT-003 Phase I trial evaluating eftilagimod alpha  in combination with KE","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/rMGJzQlu_.sxjdfFCHAlRg--~B/aD0xMDM7dz0yNDY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/caf92fc65a13b56708c85c7546e3ac3d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/rMGJzQlu_.sxjdfFCHAlRg--~B/aD0xMDM7dz0yNDY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/caf92fc65a13b56708c85c7546e3ac3d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immutep-efti-shows-excellent-survival-131500096.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7508","INAQU","BK4139","BK4097","BK7095","IMM.AU","ORR.AU","OS","BK4211","IMMP","BK4195","PFS","BK7067"],"gpt_icon":1},{"id":"2483877831","title":"Positive Data From Phase Ii Trial in Soft Tissue Sarcoma Presented at Ctos 2024 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2483877831","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483877831?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:00","pubTimestamp":1731589201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nTUAB6Q7C1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","IMM.AU"],"gpt_icon":0},{"id":"2483787758","title":"Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2483787758","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483787758?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:00","pubTimestamp":1731589200,"startTime":"0","endTime":"0","summary":"Efti in combination with pembrolizumab and radiotherapy demonstrates significant efficacy in the neoadjuvant setting in patients with soft tissue sarcoma. Over three-fold increase in tumour hyalinization, the primary endpoint of the study and an important predictor of overall survival, as compared to historical results from radiotherapy alone. SYDNEY, AUSTRALIA, Nov. 14, 2024  -- Immutep Limited  , a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the presentation of new data from EFTISARC-NEO, a Phase II investigator-initiated trial of eftilagimod alpha  in combination with radiotherapy plus KEYTRUDA  for patients with soft tissue sarcoma , at the Connective Tissue Oncology Society  2024 Annual Meeting. Based on preliminary analysis among 21 patients available for primary endpoint assessment, the triple combination therapy demonstrates significant efficacy in the neoadjuvant setting for resectable STS.Dr. F","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/rMGJzQlu_.sxjdfFCHAlRg--~B/aD0xMDM7dz0yNDY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/caf92fc65a13b56708c85c7546e3ac3d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/rMGJzQlu_.sxjdfFCHAlRg--~B/aD0xMDM7dz0yNDY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/caf92fc65a13b56708c85c7546e3ac3d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/positive-data-phase-ii-trial-130000666.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK4139","IMM.AU","BK4104","IMMP","BK7508","BK7067","CTOS"],"gpt_icon":1},{"id":"2483484957","title":"Here are the top 10 ASX 200 shares today","url":"https://stock-news.laohu8.com/highlight/detail?id=2483484957","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483484957?lang=en_us&edition=fundamental","pubTime":"2024-11-14 13:59","pubTimestamp":1731563994,"startTime":"0","endTime":"0","summary":"The S&P/ASX 200 Index (ASX: XJO) managed to snap the three-day losing streak it had been on this week to push higher today. After falling all week, ASX investors appeared to decide enough was enough t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/11/14/here-are-the-top-10-asx-200-shares-today-532/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7503","BK7047","CWY.AU","BK7016","JHX.AU","NEU.AU","RWC.AU","XJO.AU","BK7508","BK7096","FLT.AU","TAH.AU","BK7012","BK7078","CTD.AU","BK7044","BK7070","NUF.AU","BK7020","WEB.AU","XRO.AU"],"gpt_icon":1},{"id":"2483289717","title":"3 ASX Growth Stocks With Up To 12% Insider Ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2483289717","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483289717?lang=en_us&edition=fundamental","pubTime":"2024-11-14 12:05","pubTimestamp":1731557149,"startTime":"0","endTime":"0","summary":"As the ASX200 shows a modest increase of 0.45% amidst steady unemployment rates and sector-specific fluctuations, investors are keenly observing growth opportunities within the Australian market. In this environment, companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those who know the business best, aligning well with current trends in IT and Financials sectors which have shown resilience.Top 10 Growth Companies With High Insider Ownership In Australia. Click here to see the full list of 91 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.PolyNovo's earnings are forecast to grow significantly at 38.4% annually, outpacing the Australian market. Despite recent changes in executive leadership with the retirement of a long-standing director, insider activity shows more shares bought than sold recently, indicating confidence in its growth trajectory. The company reported A$104.76 million in revenu","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/DGkyMqml3gFWOGvNtEHcnA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/06bbda48bd77be658a8c5765fd6bc2ab","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/DGkyMqml3gFWOGvNtEHcnA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/06bbda48bd77be658a8c5765fd6bc2ab"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-asx-growth-stocks-12-040549607.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["3DP.AU","BK7104","GEN.AU","A4N.AU","PLT.AU","BK7043","TNE.AU","AVA.AU","BK7126","XAO.AU","HGO.AU","CYL.AU","ACR.AU","BK7017","BK7129","BK7093","BK7084","MM8.AU","BK7506","BK7503","BK7158","BK7096","BK7508","BK7016","FND.AU","XJO.AU","XKO.AU","BK7095","BTR.AU","PNV.AU"],"gpt_icon":0},{"id":"2483292896","title":"Immutep Reports Positive Data from Soft Tissue Sarcoma Trial; Shares Up 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483292896","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483292896?lang=en_us&edition=fundamental","pubTime":"2024-11-14 11:09","pubTimestamp":1731553761,"startTime":"0","endTime":"0","summary":"Biotechnology company Immutep  said its EFTISARC-NEO, a second phase trial of eftilagimod alpha in combination with radiotherapy and KEYTRUDA for patients with soft tissue sarcoma, showed positive data, according to a Thursday filing with the Australian bourse.The triple combination therapy, based on a preliminary analysis of 21 patients, showed \"significant\" efficacy in the neoadjuvant setting for resectable soft tissue sarcoma, the filing said.The study also found an over three-fold increase in tumor hyalinization, a crucial predictor of overall survival, compared with historical results from radiotherapy alone.The EFTISARC-NEO study, led by the Maria Skodowska-Curie National Research Institute of Oncology, is expected to enroll 40 patients in the first quarter of 2025, according to the filing.The new data from the study was presented at the Connective Tissue Oncology Society annual meeting, the filing added.Immutep shares rose nearly 5% in afternoon trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMM.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2483989520","title":"Immutep’s efti combination therapies show strong efficacy in soft tissue sarcoma and lung cancer trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2483989520","media":"Small Caps","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483989520?lang=en_us&edition=fundamental","pubTime":"2024-11-14 10:39","pubTimestamp":1731551943,"startTime":"0","endTime":"0","summary":"Immutep  has presented new data from a Phase II investigator-initiated trial of eftilagimod alpha  in combination with radiotherapy plus Keytruda  for patients with soft tissue sarcoma .Based on preliminary analysis of 21 patients available for primary endpoint assessment, the trial at Maria Skodowska-Curie National Research Institute of Oncology  in Poland showed that the triple-combination therapy demonstrated significant efficacy in the neoadjuvant setting for resectable STS.The combination was reported to be safe, with no serious toxicities related to efti or pembrolizumab.“We are pleased with the strength of these preliminary results in this difficult-to-treat cancer,” Immutep chief scientific officer Dr Frédéric Triebel said.“To see 71.4% of soft tissue sarcoma patients achieving a positive pathologic response is very promising, especially as strong efficacy has been observed across different STS subtypes.”Immutep has also announced positive data from an Insight-003 Phase I trial","market":"us","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/11/Immutep-ASX-IMM-eftilagimod-alpha-STS-trial-success.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/11/Immutep-ASX-IMM-eftilagimod-alpha-STS-trial-success.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://smallcaps.com.au/immutep-efti-therapies-strong-efficacy-soft-tissue-sarcoma-lung-cancer-trials/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["BK7508","BK7067","IMM.AU"],"gpt_icon":0},{"id":"2483893286","title":"Immutep Reports Positive Survival Data from Non-Small Cell Lung Cancer Study; Shares Up 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483893286","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483893286?lang=en_us&edition=fundamental","pubTime":"2024-11-14 10:20","pubTimestamp":1731550831,"startTime":"0","endTime":"0","summary":"Biotechnology company Immutep  obtained positive survival data from the Insight-003 first phase trial, evaluating eftilagimod alpha in combination with Keytruda and chemotherapy for the first-line treatment of metastatic non-squamous non-small cell lung cancer, according to a Thursday filing with the Australian bourse.The study results, with a minimum follow-up of 22 months, showed a median overall survival of 32.9 months, a median progression-free survival of 12.7 months, and a 24-month overall survival rate of 81%, the filing said.Results also show no new safety signals.Insight-003, led by the Frankfurt Institute of Clinical Cancer Research, is nearing patient enrollment completion, with further data from the trial expected in 2025, according to the filing.Immutep shares rose past 8% in midday trade Thursday.Price : $0.34, Change: $+0.03, Percent Change: +8.06%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1043141123.HKD","LU0345774631.USD","LU0994945656.USD","LU2238339852.HKD","BK7067","BK4125","BK7508","LU0426412945.USD","AUD","LU0426417589.USD","IMM.AU"],"gpt_icon":0},{"id":"2483689331","title":"Neuren Pharmaceuticals to Launch AU$50 Million Share Buyback; Shares Up 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483689331","media":"MT Newswires Live","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483689331?lang=en_us&edition=fundamental","pubTime":"2024-11-14 10:08","pubTimestamp":1731550114,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  plans to launch a share buyback program of up to 3 million shares worth AU$50 million for up to 12 months, according to a Thursday filing with the Australian bourse.The shares to be acquired represent 2.4% of the company's total shares in issue.The capital deployment comes as the company is poised to receive one-third of the proceeds from the sale of Neuren licensee Acadia Pharmaceuticals' Rare Pediatric Disease Priority Review Voucher for $150 million, the filing said.The pharmaceutical company's shares were up more than 5% in recent Thursday trade.Price : $17.44, Change: $+0.90, Percent Change: +5.44%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0426412945.USD","BK7508","LU0426417589.USD","LU1043141123.HKD","BK7096","LU0994945656.USD","NEU.AU","AUD","LU2238339852.HKD","LU0345774631.USD","BK4125"],"gpt_icon":0},{"id":"2483385898","title":"Botanix Pharmaceuticals Says US Payer Group to Cover Its Excessive Sweat Medication; Shares Up 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483385898","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483385898?lang=en_us&edition=fundamental","pubTime":"2024-11-14 09:40","pubTimestamp":1731548434,"startTime":"0","endTime":"0","summary":"Botanix Pharmaceuticals  said US payer organization Ascent Health will cover its Sofdra-branded sofpironium topical gel, 12.45%, for the treatment of primary axillary hyperhidrosis, or excessive sweating, according to a Thursday filing with the Australian bourse.Ascent Health is the second largest payer in the US covering 65 million people, the filing said. The company is advancing reimbursement coverage deals with other payers.Botanix Pharmaceuticals' shares rose past 6% in recent Thursday trade.Price : $0.34, Change: $+0.02, Percent Change: +6.25%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0426417589.USD","AUD","BK7508","LU0994945656.USD","LU0345774631.USD","LU1043141123.HKD","LU2238339852.HKD","LU0426412945.USD","BOT.AU","BK7096","BK7502","BK4125"],"gpt_icon":0},{"id":"2483860830","title":"3 ASX healthcare shares going gangbusters on Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=2483860830","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483860830?lang=en_us&edition=fundamental","pubTime":"2024-11-14 09:00","pubTimestamp":1731546012,"startTime":"0","endTime":"0","summary":"Three ASX healthcare shares are making their shareholders very happy today, posting gains of 5%, 12% and 19% respectively in morning trade. And this strong performance comes despite some broader healthcare sector headwinds on Thursday, which sees the S&P/ASX 200 Health Care Index  down 0.4% at this same time. So, which three ASX healthcare shares are bucking the trend and flying higher?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/11/14/3-asx-healthcare-shares-going-gangbusters-on-thursday/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["MSB.AU","NEU.AU","IMM.AU","BK7501","BK7067","BK7096","BK7508"],"gpt_icon":1},{"id":"2483645668","title":"BUZZ-Australia's Neuren Pharma hits over 3-month high on $32 mln share buyback","url":"https://stock-news.laohu8.com/highlight/detail?id=2483645668","media":"reuters","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483645668?lang=en_us&edition=fundamental","pubTime":"2024-11-14 07:47","pubTimestamp":1731541644,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Neuren Pharma hits over 3-month high on $32 mln share buyback ** Shares of Neuren Pharmaceuticals NEU.AX rise as much as 8.4% to A$17.940, their highest since Aug. 5** Stock biggest pct gainer on the benchmark S&P/ASX 200 index .AXJO ** Drug manufacturer announces commencement of on-market share buyback programme of up to A$50 mln ** Says will buy up to 3 mln shares at A$16.540 per share, based on the last close of Wednesday** Stock down 33.8% YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nL4N3MK2A2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","NEU.AU","BK7096"],"gpt_icon":0},{"id":"2483940866","title":"BRIEF-Neuren Pharmaceuticals Announces A$50M On-Market Share Buy-Back Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2483940866","media":"reuters","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483940866?lang=en_us&edition=fundamental","pubTime":"2024-11-14 06:14","pubTimestamp":1731536090,"startTime":"0","endTime":"0","summary":"BRIEF-Neuren Pharmaceuticals Announces A$50M On-Market Share Buy-Back ProgramNov 14 (Reuters) - Neuren Pharmaceuticals Ltd NEU.AX:ANNOUNCES A$50M ON-MARKET SHARE BUY-BACK PROGRAMFurther company coverage: NEU.AX","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nFWN3MK340:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","BK7508","NEU.AU"],"gpt_icon":0},{"id":"2483986698","title":"Neuren Pharmaceuticals Ltd - Announces a$50M on-Market Share Buy-Back Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2483986698","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483986698?lang=en_us&edition=fundamental","pubTime":"2024-11-14 06:14","pubTimestamp":1731536056,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nFWN3MK340:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","NEU.AU","BK7096"],"gpt_icon":0},{"id":"2483101020","title":"High Growth Tech Stocks in Australia for November 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483101020","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483101020?lang=en_us&edition=fundamental","pubTime":"2024-11-13 12:06","pubTimestamp":1731470812,"startTime":"0","endTime":"0","summary":"As the Australian market faces a slight downturn with the ASX200 down 1.1% and sectors like Financials and Health Care underperforming, investors are keeping a close eye on economic indicators such as the wage price index, which has shown modest growth. In this environment, identifying high-growth tech stocks becomes crucial as these companies often have the potential to outperform due to their innovative capabilities and adaptability in fluctuating market conditions.Click here to see the full list of 59 stocks from our ASX High Growth Tech and AI Stocks screener.Overview: Opthea Limited is a clinical-stage biopharmaceutical company focused on developing and commercializing drugs for eye diseases in Australia and the United States, with a market cap of A$1.02 billion.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/gnGTQ_q9KCdl7Xvx_ppB0g--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/0fe4d5d105492213ce106a92b49639d4","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/gnGTQ_q9KCdl7Xvx_ppB0g--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/0fe4d5d105492213ce106a92b49639d4"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/high-growth-tech-stocks-australia-040652537.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["XKO.AU","OPT","BK7067","BK4139","BK7508","BK7503","NXL.AU","XAO.AU","XRO.AU","BK7016","XJO.AU","OPT.AU"],"gpt_icon":0},{"id":"2483012905","title":"Does the Vanguard Australian Shares ETF (VAS) pay fully franked dividends?","url":"https://stock-news.laohu8.com/highlight/detail?id=2483012905","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483012905?lang=en_us&edition=fundamental","pubTime":"2024-11-13 11:18","pubTimestamp":1731467921,"startTime":"0","endTime":"0","summary":"The Vanguard Australian Shares Index ETF  currently  occupies the perch as the ASX's most popular index fund. Obviously, many ASX investors find this fund appealing.This appeal might come down to a few different reasons. Perhaps investors like the diversification that this ASX 300-tracking fund offers. Perhaps it's the slow but steady track record of growth that VAS has delivered for decades now. Or perhaps it is this fund's dividend potential that investors find appealing.As a representation of the broad Australian stock market, the Vanguard Australian Shares Index ETF has always been a decent investment when it comes to dividend income. After all, the top shares in this exchange-traded fund  include the likes of BHP Group Ltd , Commonwealth Bank of Australia , Westpac Banking Corp  and Woodside Energy Group Ltd .Over the past 12 months, VAS has indeed given ASX investors four dividend distribution payments totalling $3.27 per unit. That gives this ASX index fund a trailing dividend d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/11/13/does-the-vanguard-australian-shares-etf-vas-pay-fully-franked-dividends/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7142","XJO.AU","BK7095","BK7501","BK7511","FDN","BK7046","CSL.AU","ANZ.AU","BHP.AU","XKO.AU","BK7507","BK4550","CBA.AU","ETF.AU","VAS.AU","MQG.AU","XAO.AU","BK7135","BK4588","WBC.AU","TCL.AU","BK7090","BK7508","BK4585","WDS.AU","BK7067"],"gpt_icon":0},{"id":"2483101366","title":"Avita Medical Signs Exclusive Deal with Australian Medical Device Distributor; Shares Up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483101366","media":"MT Newswires Live","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483101366?lang=en_us&edition=fundamental","pubTime":"2024-11-13 10:25","pubTimestamp":1731464727,"startTime":"0","endTime":"0","summary":"Avita Medical  signed an exclusive agreement with Revolution Surgical for the distribution of the Recell product platform for thermal burn wound treatment, according to a Wednesday filing with the Australian bourse.Revolution Surgical will be the exclusive distributor of Recell products in Australia and New Zealand under the deal, the filing said.Avita Medical shares rose nearly 4% in midday trade Wednesday.Price : $3.81, Change: $+0.13, Percent Change: +3.53%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XKO.AU","BK7067","BK7508","XAO.AU","LU0345774631.USD","AUD","LU0426412945.USD","LU2238339852.HKD","LU0994945656.USD","LU0426417589.USD","XJO.AU","BK4125","LU1043141123.HKD","AVH.AU"],"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":-0.0252},{"period":"3month","weight":-0.022},{"period":"6month","weight":-0.0006},{"period":"1year","weight":0.1369},{"period":"ytd","weight":0.1205}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"name":"BK7508","nameEN":"BK7508"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Pharmaceutical Companies(BK7508),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Pharmaceutical Companies(BK7508) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Pharmaceutical Companies,BK7508,Pharmaceutical Companies股票,Pharmaceutical Companies股票老虎,Pharmaceutical Companies股票老虎国际,Pharmaceutical Companies行情,Pharmaceutical Companies股票行情,Pharmaceutical Companies股价,Pharmaceutical Companies股市,Pharmaceutical Companies股票价格,Pharmaceutical Companies股票交易,Pharmaceutical Companies股票购买,Pharmaceutical Companies股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Pharmaceutical Companies(BK7508),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Pharmaceutical Companies(BK7508) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction